Sutro Biopharma, Inc. (STRO) annual balance sheet — 10-year assets, liabilities & equity history
| Total Current Assets | 220.97M | 150.93M | 343.31M | 421.54M | 353.15M | 218.51M | 378.18M | 128.57M | 209.95M | 25.63M | 49.69M |
| Cash & Short-Term Investments | 202.56M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M | 368.14M | 117.86M | 204.49M | 22.02M | 47.52M |
| Cash Only | 73.68M | 58.13M | 190.3M | 69.27M | 47.25M | 30.41M | 206.15M | 4.96M | 125.3M | 22.02M | 11.59M |
| Short-Term Investments | 128.88M | 83.3M | 126.59M | 306.35M | 287.11M | 167.52M | 161.99M | 112.9M | 79.19M | 0 | 35.93M |
| Accounts Receivable | 12.48M | 3.98M | 8.62M | 36.08M | 7.12M | 12.45M | 5.56M | 6.3M | 2.49M | 1.62M | 577K |
| Days Sales Outstanding | 26 | 14.16 | 50.69 | 85.66 | 38.36 | 73.46 | 47.49 | 53.79 | 23.65 | 11.46 | 3.53 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 5.93M | 5.52M | 17.8M | 9.85M | 11.67M | 0 | 0 | 4.41M | 2.96M | 0 | 0 |
| Total Non-Current Assets | 21.02M | 22.9M | 43.9M | 49.19M | 53.79M | 122.89M | 15.93M | 27.8M | 13.19M | 15.14M | 19.59M |
| Property, Plant & Equipment | 19.07M | 21.55M | 35.87M | 44.76M | 51.06M | 51.59M | 12.94M | 9.63M | 10.93M | 14M | 18.69M |
| Fixed Asset Turnover | 4.10x | 4.76x | 1.73x | 3.43x | 1.33x | 1.20x | 3.30x | 4.44x | 3.51x | 3.70x | 3.20x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.72M | 0 | 0 | 0 | -32.02M | 68.78M | 0 | 15.62M | 15K | 223K | 482K |
| Other Non-Current Assets | 1.95M | 1.35M | 8.03M | 4.44M | 34.75M | 2.53M | 2.99M | 2.54M | 2.24M | 920K | 417K |
| Total Assets | 241.99M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M | 394.11M | 156.37M | 223.14M | 40.77M | 69.28M |
| Asset Turnover | 0.45x | 0.59x | 0.16x | 0.33x | 0.17x | 0.18x | 0.11x | 0.27x | 0.17x | 1.27x | 0.86x |
| Asset Growth % | -179.77% | -55.11% | -17.74% | 15.68% | 19.2% | -13.37% | 152.04% | -29.92% | 447.33% | -41.15% | - |
| Total Current Liabilities | 70.81M | 75.13M | 131.89M | 93.75M | 66.55M | 41.74M | 29.6M | 32.97M | 36.42M | 31.96M | 50.18M |
| Accounts Payable | 5.49M | 7.57M | 10.47M | 9.44M | 4.8M | 6.01M | 5.54M | 5.58M | 3.06M | 2.9M | 3.39M |
| Days Payables Outstanding | 1.74K | 377.01 | 529.7 | 505.52 | 211.26 | 224.42 | 26.29 | - | 20.59 | 20.41 | 28.45 |
| Short-Term Debt | 7.6M | 7.78M | 0 | 4.06M | 17.09M | 9.38M | 0 | 1M | 4.72M | 14.56M | 0 |
| Deferred Revenue (Current) | 40.9M | 10.56M | 69.78M | 20.67M | 16.76M | 5.5M | 14.6M | 19.46M | 21.57M | 10.71M | 43.58M |
| Other Current Liabilities | 48.33M | 49.22M | 16.91M | 18.58M | 11.64M | 11.42M | 627K | 901K | 7.06M | 143K | 22K |
| Current Ratio | 3.12x | 2.01x | 2.60x | 4.50x | 5.31x | 5.24x | 12.78x | 3.90x | 5.76x | 0.80x | 0.99x |
| Quick Ratio | 3.12x | 2.01x | 2.60x | 4.50x | 5.31x | 5.24x | 12.78x | 3.90x | 5.76x | 0.80x | 0.99x |
| Cash Conversion Cycle | -1.72K | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 238.06M | 231.15M | 210.71M | 227.34M | 123.35M | 47.11M | 32.47M | 25.61M | 55.18M | 117.81M | 110M |
| Long-Term Debt | 6.03M | 7.89M | 0 | 0 | 3.77M | 15.74M | 24.55M | 8.88M | 10M | 0 | 0 |
| Capital Lease Obligations | 19.43M | 0 | 15.67M | 23.15M | 29.57M | 31.22M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 476K | 0 | -1.19M |
| Other Non-Current Liabilities | 232.03M | 223.26M | 1.69M | 1.69M | 119K | 146K | 1.82M | 543K | 578K | 104.66M | 104.14M |
| Total Liabilities | 308.88M | 306.28M | 342.61M | 321.09M | 189.9M | 88.84M | 62.06M | 58.58M | 91.6M | 149.77M | 160.18M |
| Total Debt | 13.63M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M | 24.55M | 9.88M | 14.72M | 14.63M | 1.19M |
| Net Debt | -60.05M | -42.46M | -167.15M | -35.63M | 7.76M | 26.96M | -181.61M | 4.92M | -110.57M | -7.39M | -10.4M |
| Debt / Equity | -0.20x | - | 0.52x | 0.22x | 0.25x | 0.23x | 0.07x | 0.10x | 0.11x | - | - |
| Debt / EBITDA | -0.13x | - | - | - | - | - | - | - | - | - | 0.17x |
| Net Debt / EBITDA | 0.55x | - | - | - | - | - | - | - | - | - | -1.48x |
| Interest Coverage | -2.85x | -2.75x | -6.04x | -3.15x | -33.88x | -32.64x | -7.06x | -11.81x | -23.26x | -27.69x | - |
| Total Equity | -66.89M | -132.45M | 44.6M | 149.65M | 217.05M | 252.56M | 332.05M | 97.79M | 131.54M | -109M | -90.9M |
| Equity Growth % | -855.68% | -396.97% | -70.2% | -31.05% | -14.06% | -23.94% | 239.56% | -25.66% | 220.68% | -19.91% | - |
| Book Value per Share | -5.11 | -15.59 | 5.81 | 24.87 | 42.78 | 54.76 | 101.94 | 42.59 | 57.53 | -155.77 | -2060.31 |
| Total Shareholders' Equity | -66.89M | -132.45M | 44.6M | 149.65M | 217.05M | 252.56M | 332.05M | 97.79M | 131.54M | -109M | -90.9M |
| Common Stock | 17K | 9K | 83K | 61K | 58K | 46K | 46K | 23K | 23K | 0 | 16K |
| Retained Earnings | -1.02B | -977.96M | -786.87M | -559.41M | -452.62M | -333.41M | -227.87M | -195.75M | -150.33M | -115.01M | -95.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -101K | 19K | 39K | 21K | -618K | -314K | 129K | 165K | -47K | -208K | -17K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying STRO stock.
As of 2025, Sutro Biopharma, Inc. (STRO) had total assets of $173.8M including $150.9M in current assets.
Sutro Biopharma, Inc. (STRO) carries total debt of $15.7M, offset by $141.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Sutro Biopharma, Inc. (STRO) has total shareholders' equity (book value) of $-132.5M ($-15.59 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Sutro Biopharma, Inc. (STRO) reported a current ratio of 2.01x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.